Volume & money flow · daily rule · Healthcare
Money Flow Index on Alnylam Pharmaceuticals
ALNY with the play, last two years
Shading shows the play's call from the close that triggered it.
Money Flow Index (14)
Dashed lines at 20, 80.
Growth of $10,000 since 2005
Log scale. After trading costs, with T-bill interest while out.
The record
The play against buying and holding ALNY over exactly the same dates, after costs.
| Play, since 2005 | Hold, since 2005 | Play, 5 yrs | Hold, 5 yrs | |
|---|---|---|---|---|
| Annual return | +13.6% | +16.9% | +17.9% | +1.9% |
| Total return | +1,489% | +2,853% | +126% | +10% |
| Worst drawdown | −52.2% | −83.6% | −39.7% | −58.2% |
| Volatility | 35.8% | 56.8% | 38.3% | 50.9% |
| Sharpe ratio | 0.48 | 0.52 | 0.50 | 0.21 |
| Time invested | 42% | 100% | ||
| Switches per year | 2.4 | 0 |
Every call, graded
Right on 30 of 52 closed calls (58%). In calls averaged +12.7%; out calls saw ALNY move +10.0% on average.
| Called | Call | Price | Until | ALNY moved | Result |
|---|---|---|---|---|---|
| Jul 10, 2026 | OUT | $298.76 | now | −25.1% | open |
| Feb 13, 2026 | IN | $314.40 | Jul 10, 2026 | −5.0% | ✕ wrong |
| Mar 25, 2025 | OUT | $280.96 | Feb 13, 2026 | +11.9% | ✕ wrong |
| Feb 24, 2025 | IN | $248.94 | Mar 25, 2025 | +12.9% | ✓ right |
| Jul 1, 2024 | OUT | $243.32 | Feb 24, 2025 | +2.3% | ✕ wrong |
| Sep 29, 2023 | IN | $177.10 | Jul 1, 2024 | +37.4% | ✓ right |
| Apr 12, 2023 | OUT | $202.89 | Sep 29, 2023 | −12.7% | ✓ right |
| Feb 28, 2023 | IN | $191.45 | Apr 12, 2023 | +6.0% | ✓ right |
| Aug 23, 2022 | OUT | $216.89 | Feb 28, 2023 | −11.7% | ✓ right |
| Nov 2, 2021 | IN | $167.65 | Aug 23, 2022 | +29.4% | ✓ right |
| Jan 27, 2021 | OUT | $155.39 | Nov 2, 2021 | +7.9% | ✕ wrong |
| Nov 4, 2020 | IN | $139.49 | Jan 27, 2021 | +11.4% | ✓ right |
An in call is right when the price rose before the next call; an out call is right when it fell. The latest 12 of 53 calls shown.
How the play works
- In when the 14-day MFI crosses up through 20.
- Out when it crosses down through 80.
The creators also stress divergences, which this rule ignores.
The case against
Valeriy Zakamulin tested moving-average timing on up to 155 years of U.S. stock data and found no statistically significant edge in the second half of that record. The rules earned their keep in a few severe bear markets and lagged buy and hold for long stretches in between.